[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619184":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":24,"locations":34,"responsibleParty":99,"collaborators":101,"id":110,"slug":10,"hasResults":111,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":111,"sex":117,"minAge":10,"maxAge":10,"enrollmentInfo":118,"targetDuration":10,"studyType":121,"phases":10,"briefSummary":122,"conditions":123,"keywords":127,"overallStatus":132,"whyStopped":10,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},{"fullName":5,"class":6},"Medical University of Graz","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Vaccinated",null,"Patients with hepatocellular carcinoma, undergoing checkpoint inhibitor therapy, vaccinated with mRNA vaccine within last 100 days",{"label":13,"type":10,"description":14,"interventionNames":10},"not vaccinated","Patients with hepatocellular carcinoma, undergoing checkpoint inhibitor therapy, not vaccinated with mRNA vaccine within last 100 days",[16,20,22],{"name":17,"affiliation":18,"role":19},"Florian Rainer, MD","Medizinische Universität Graz","PRINCIPAL_INVESTIGATOR",{"name":21,"affiliation":18,"role":19},"Vanessa Stadlbauer, Univ Prof",{"name":23,"affiliation":18,"role":19},"Walter Spindelböck, MD",[25,30],{"name":17,"role":26,"phone":27,"phoneExt":28,"email":29},"CONTACT","+43 316 385","30164","florian.rainer@medunigraz.at",{"name":31,"role":26,"phone":27,"phoneExt":32,"email":33},"Vanessa Stadlbauer, Univ. Prof. MD","82282","vanessa.stadlbauer@medunigraz.at",[35,47,60,73,86],{"facility":5,"status":10,"city":36,"state":10,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Graz","8010","Austria",{"type":40,"coordinates":41},"Point",[42,43],15.44197,47.06733,{"lat":43,"lon":42},[46],{"name":17,"role":26,"phone":27,"phoneExt":10,"email":29},{"facility":48,"status":10,"city":49,"state":10,"zip":10,"country":38,"cosmosGeoPoint":50,"geoPoint":54,"contacts":55},"Ordensklinikum Linz","Linz",{"type":40,"coordinates":51},[52,53],14.28611,48.30639,{"lat":53,"lon":52},[56],{"name":57,"role":26,"phone":58,"phoneExt":10,"email":59},"Stephanie Hametner-Schreil","+43 732 7677","Stephanie.Hametner-Schreil@ordensklinikum.at",{"facility":61,"status":10,"city":62,"state":10,"zip":10,"country":38,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"University Hospital St. Pölten","Sankt Pölten",{"type":40,"coordinates":64},[65,66],15.63725,48.20762,{"lat":66,"lon":65},[69],{"name":70,"role":26,"phone":71,"phoneExt":10,"email":72},"Anderas Maieron, MD","+43 27429004","andreas.maieron@stpoelten.lknoe.at",{"facility":74,"status":10,"city":75,"state":10,"zip":10,"country":38,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Krankenhaus der Barmherzigen Brüder St Veit an der Glan","Sankt Veit an der Glan",{"type":40,"coordinates":77},[78,79],14.36028,46.76806,{"lat":79,"lon":78},[82],{"name":83,"role":26,"phone":84,"phoneExt":10,"email":85},"Ute Enökl-Tomantschger, MD","+43 4212 499","Ute.Enoekl-Tomantschger@bbstveit.at",{"facility":87,"status":10,"city":88,"state":10,"zip":10,"country":38,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"Klinikum Wels-Grieskirchen","Wels",{"type":40,"coordinates":90},[91,92],14.03333,48.16667,{"lat":92,"lon":91},[95],{"name":96,"role":26,"phone":97,"phoneExt":10,"email":98},"Harald Hofer, MD","+43 7242 415 - 2181","harald.hofer@klinikum-wegr.at",{"type":100,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[102,103,105,108],{"name":87,"class":6},{"name":104,"class":6},"University Hospital St. Polten",{"name":106,"class":107},"Ordensklinikum Linz GmbH Krankenhaus Barmherzige Schwestern","UNKNOWN",{"name":109,"class":107},"Krankenhaus der Barmherzigen Brüder St. Veit\u002FGlan","100619184",false,"NCT07341321","SARS-CoV-2 mRNA Vaccination in Patients With Hepatocellular Carcinoma Treated With Immune Checkpoint Inhibitors","SARS-CoV-2 mRNA Vaccination in Patients With Hepatocellular Carcinoma Treated With Immune Checkpoint Inhibitors (CoVaCheck) A Multicenter Retrospective Cohort Analysis in Austria","CoVaCheck","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Radiologically or histologically confirmed hepatocellular carcinoma\n* Treatment with immune checkpoint inhibitor-based therapy (mono- or combination therapy; e.g., atezolizumab\u002Fbevacizumab, durvalumab\u002Ftremelimumab, nivolumab, pembrolizumab)\n* Complete electronic medical records available\n* At least one imaging-based response assessment using mRECIST\n\nExclusion Criteria:\n\n* Missing key clinical data required for main analyses (e.g. survival status, date of progression, Child-Pugh class, BCLC stage)","ALL",{"count":119,"type":120},200,"ESTIMATED","OBSERVATIONAL","A multicenter retrospective cohort analysis in Austria\n\nPrimary Objective:\n\nTo assess whether receiving an mRNA COVID-19 vaccine within 3 months before starting ICI (Immune checkpoint inhibitors) therapy improves best overall response (mRECIST) in HCC (hepatocellular carcinoma).\n\nSecondary Objectives:\n\nEvaluate whether vaccination within 1 or 3 months affects OS (overall survival) , PFS (Progression free survival)), or TTP (Time to progression); compare outcomes by vaccination status, vaccine type, and prior infection; explore modification by cirrhosis severity and tumor characteristics; and assess safety (irAEs, steroid use, toxicity-related discontinuation).",[124,125,126],"mRNA Vaccination","Hepatocellular Carcinoma","Checkpoint Inhibitor",[128,129,130,131],"hepatocellular carcinoma","mRNA vaccination","response","immune checkpoint inhibitor","NOT_YET_RECRUITING","2026-01-07",{"date":135,"type":136},"2026-01-14","ACTUAL",{"date":138,"type":120},"2026-01",{"date":140,"type":120},"2026-12",{"name":5,"class":6},5]